Contribute Try STAT+ Today

The Brazilian Supreme Court ruled that a provision in the country’s intellectual property law allowing lengthy extensions on patents is unconstitutional, a move that is expected to clear the way for lower-cost generic versions of some drugs to become available sooner.

The decision came in a closely watched case that has pitted the pharmaceutical industry and consumer advocates against each other in a fight over the Brazilian patent system and the extent to which many prescription drugs are affordable. Studies have found that revoking the provision would help reduce government spending on medicines and reduce hurdles faced by the generic drug industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.